NanoVibronix Inc (OQ:NAOV)
Business Focus: Medical Equipment, Supplies & Distribution
| Sector: Healthcare | Industry: Medical Equipment, Supplies & Distribution |
| See Regulatory Filings on SEC | |
| Company Contact | |
| Address: | 525 Executive Blvd ELMSFORD NY 10523 |
| Tel: | N/A |
| Website: | https://nanovibronix.com |
| IR: | See website |
| Key People | ||
| Brian M. Murphy Chief Executive Officer, Director | Stephen Russell Brown Chief Financial Officer | Harold Jacob Chief Medical Officer, Director |
| Business Overview |
| NanoVibronix, Inc. is a medical device company. The Company is focused on developing noninvasive biological response-activating devices utilizing its low-intensity surface acoustic wave (SAW) technology. Its primary products consist of UroShield and PainShield. UroShield is an ultrasound-based product that is designed to prevent bacterial colonization and biofilm in urinary catheters, increase antibiotic efficacy and decrease pain and discomfort associated with urinary catheter use, which markets in the United States under Food and Drug Administration (FDA) policy of enforcement discretion during the COVID-19 pandemic and is undergoing clinical testing. PainShield is a patch-based therapeutic ultrasound technology to treat pain, muscle spasm and joint contractures by delivering a localized ultrasound effect to treat pain and induce soft tissue healing in a targeted area. Its PainShield family of products includes PainShield MD and PainShield Plus. |
| Financial Overview |
| For the fiscal year ended 31 December 2023, NanoVibronix Inc revenues increased from $752K to $2.3M. Net loss decreased 32% to $3.7M. Revenues reflect United States segment increase from $710K to $2.2M, Europe segment increase from $25K to $101K. Lower net loss reflects Selling and Marketing - Balancing value decrease of 11% to $836K (expense), Research & development decrease of 35% to $179K (expense). |
| Employees: | 10 as of Apr 8, 2024 |
| Reporting Currency: | U.S. Dollars |
| Enterprise value: | N/A |
| Annual revenue (TTM): | $2.28M as of Dec 31, 2023 |
| EBITDA (TTM): | -$3.44M as of Dec 31, 2023 |
| Net annual income (TTM): | -$3.71M as of Dec 31, 2023 |
| Free cash flow (TTM): | -$3.60M as of Dec 31, 2023 |
| Net Debt Last Fiscal Year: | N/A |
| Shares outstanding: | 2,784,354 as of Apr 8, 2024 |
| TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization | |
Disclaimer :: Use of this site is subject to, and your continued use
constitutes your express agreement to be bound by, our Legal and Terms of Use. Any commercial use of this site is
strictly prohibited. Insidertracking.com is operated by INK Research Corp (INK). INK provides general information.
INK has made all reasonable efforts to ensure that all information provided is accurate at the time of inclusion;
however, there may be errors. INK makes no guarantee of accuracy or completeness. All information and opinion
expressed herein is subject to change without notice. Insider information is based on filings made either on EDGAR®
or on the System for Electronic Disclosure for Insiders (SEDI®). Data is provided “as is” and by using this site
you acknowledge that the information which comprises the data is filed by or on behalf of the SEDI filers or other
parties legally required or permitted to do so. Filings may at any time contain errors and by using this site you
acknowledge this fact. INK is not an investment advisory service, a financial planner, an investment advisor nor a
securities advisor. INK does not purport to tell people, or suggest to people, what they should buy or sell for
themselves. Opinions and recommendations contained herein should not be construed as investment advice. Do not
assume that any recommendations, insights, charts, theories, or philosophies will ensure profitable investment.
Users should always consult with and obtain advice from their professional licensed financial advisor, including
their tax advisor, to determine the suitability of any investment. INK recommends that anyone making an investment
or trading securities do so with caution. Users should perform full due diligence and investigate any security
fully before making an investment or before the execution of a security trade based upon information learned
through INK. Investors should obtain annual reports and other company information to complete their own due
diligence in any investment. Neither INK nor anyone affiliated with INK is responsible for any investment decision
made. INK employees may have an ownership or investment interest in any stock mentioned in this service or on this
website. On this site, there may be third party content, content from authors or links to third-party sites or
pages, the contents of which are not verified, maintained, controlled or supervised by INK. INK is not responsible
for and assumes no liability for the accuracy, completeness or timeliness of any third party content or authored
content provided herein or the information or contents of any linked sites or pages. The inclusion of any authored
content or link by us does not imply that INK recommends, approves or endorses the authored content or linked site
or pages. INK Edge® and INK Research® are registered trade-marks owned by INK Research Corp. SEDI®
is a registered trade-mark owned by the Alberta Securities Commission. Copyright © 2024 INK Research Corp. All rights reserved.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.